SG11201708303XA - Compounds targeting proteins, compositions, methods, and uses thereof - Google Patents
Compounds targeting proteins, compositions, methods, and uses thereofInfo
- Publication number
- SG11201708303XA SG11201708303XA SG11201708303XA SG11201708303XA SG11201708303XA SG 11201708303X A SG11201708303X A SG 11201708303XA SG 11201708303X A SG11201708303X A SG 11201708303XA SG 11201708303X A SG11201708303X A SG 11201708303XA SG 11201708303X A SG11201708303X A SG 11201708303XA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- compounds targeting
- targeting proteins
- proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562165469P | 2015-05-22 | 2015-05-22 | |
| PCT/US2016/033133 WO2016191178A1 (en) | 2015-05-22 | 2016-05-18 | Compounds targeting proteins, compositions, methods, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201708303XA true SG11201708303XA (en) | 2017-11-29 |
Family
ID=56194555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201708303XA SG11201708303XA (en) | 2015-05-22 | 2016-05-18 | Compounds targeting proteins, compositions, methods, and uses thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9822098B2 (en) |
| EP (1) | EP3298004B1 (en) |
| JP (2) | JP6629885B2 (en) |
| KR (1) | KR102055491B1 (en) |
| CN (1) | CN107787320B (en) |
| AU (1) | AU2016266942B2 (en) |
| CA (1) | CA2986141C (en) |
| HK (1) | HK1253065A1 (en) |
| IL (1) | IL255589B (en) |
| MX (1) | MX2017014567A (en) |
| NZ (1) | NZ737355A (en) |
| RU (1) | RU2694895C2 (en) |
| SG (1) | SG11201708303XA (en) |
| TW (1) | TWI650320B (en) |
| WO (1) | WO2016191178A1 (en) |
| ZA (1) | ZA201707749B (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2986141C (en) | 2015-05-22 | 2020-07-28 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| CN109475528B (en) | 2016-04-22 | 2022-01-11 | 达纳-法伯癌症研究所股份有限公司 | Bifunctional molecules for EGFR degradation and methods of use |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| WO2017201069A1 (en) | 2016-05-18 | 2017-11-23 | Biotheryx, Inc. | Oxoindoline derivatives as protein function modulators |
| EP3559005A1 (en) | 2016-12-21 | 2019-10-30 | Biotheryx Inc. | Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof |
| WO2018169777A1 (en) * | 2017-03-14 | 2018-09-20 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| CN110769822A (en) | 2017-06-20 | 2020-02-07 | C4医药公司 | N/O-linked degron and degron bodies for protein degradation |
| TWI793151B (en) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| US10513515B2 (en) * | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
| CN111315735B (en) | 2017-09-04 | 2024-03-08 | C4医药公司 | Dihydrobenzimidazolone |
| CN111278815B (en) | 2017-09-04 | 2024-03-08 | C4医药公司 | Glutarimide |
| WO2019043208A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | Dihydroquinolinones |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | Degraders and degrons for targeted protein degradation |
| WO2019126704A1 (en) * | 2017-12-22 | 2019-06-27 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same |
| WO2019173224A1 (en) * | 2018-03-05 | 2019-09-12 | Biotheryx, Inc. | Deuterated compounds and chimeras and uses thereof |
| KR20210018199A (en) | 2018-03-26 | 2021-02-17 | 씨4 테라퓨틱스, 인코포레이티드 | Cerevlon binder for decomposition of Ikaros |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| JP7365059B2 (en) * | 2018-06-13 | 2023-10-19 | バイオセリックス， インコーポレイテッド | Fused thiophene compound |
| AR116109A1 (en) | 2018-07-10 | 2021-03-31 | Novartis Ag | DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME |
| SG11202011872QA (en) | 2018-07-10 | 2021-01-28 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases |
| EP3830093A1 (en) | 2018-07-27 | 2021-06-09 | Biotheryx, Inc. | Bifunctional compounds as cdk modulators |
| WO2020102195A1 (en) * | 2018-11-13 | 2020-05-22 | Biotheryx, Inc. | Substituted isoindolinones |
| CN114728950A (en) | 2019-11-19 | 2022-07-08 | 百时美施贵宝公司 | Compounds useful as inhibitors of HELIOS proteins |
| US11897930B2 (en) | 2020-04-28 | 2024-02-13 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
| MX2023003114A (en) * | 2020-09-23 | 2023-03-23 | St Jude Childrens Res Hospital Inc | Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5- yl)arylsulfonamide analogs as modulators of cereblon protein. |
| PE20231941A1 (en) | 2021-04-06 | 2023-12-05 | Bristol Myers Squibb Co | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552397A (en) * | 1992-05-18 | 1996-09-03 | E. R. Squibb & Sons, Inc. | Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase |
| WO1997038705A1 (en) * | 1996-04-12 | 1997-10-23 | Bristol-Myers Squibb Company | N-formyl hydroxylamine containing compounds useful as ace inhibitors and/or nep inhibitors |
| EP2070920B8 (en) * | 1996-07-24 | 2011-04-27 | Celgene Corporation | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels |
| TR200101503T2 (en) * | 1998-03-16 | 2002-06-21 | Celgene Corporation | 2- (2,6-dioxopiperidin-3-yl) isoindoline derivatives, their preparation and use as inhibitors of inflammatory cytokines |
| WO2008070161A1 (en) | 2006-12-06 | 2008-06-12 | The Research Foundation Of State University Of New York | Azepans and methods for making and using same |
| MX2015007051A (en) | 2012-12-07 | 2016-01-12 | Chemocentryx Inc | Diazole lactams. |
| CN104004122B (en) * | 2014-05-08 | 2016-05-11 | 中国科学院长春应用化学研究所 | Novel temperature-sensitive polymer and prepare the method for Novel temperature-sensitive polymer with renewable resource 1B |
| CA2986141C (en) | 2015-05-22 | 2020-07-28 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2017201069A1 (en) | 2016-05-18 | 2017-11-23 | Biotheryx, Inc. | Oxoindoline derivatives as protein function modulators |
-
2016
- 2016-05-18 CA CA2986141A patent/CA2986141C/en active Active
- 2016-05-18 MX MX2017014567A patent/MX2017014567A/en unknown
- 2016-05-18 EP EP16731691.8A patent/EP3298004B1/en active Active
- 2016-05-18 RU RU2017139768A patent/RU2694895C2/en active
- 2016-05-18 AU AU2016266942A patent/AU2016266942B2/en active Active
- 2016-05-18 US US15/158,340 patent/US9822098B2/en active Active
- 2016-05-18 CN CN201680028266.4A patent/CN107787320B/en active Active
- 2016-05-18 KR KR1020177032154A patent/KR102055491B1/en active IP Right Grant
- 2016-05-18 WO PCT/US2016/033133 patent/WO2016191178A1/en active Application Filing
- 2016-05-18 SG SG11201708303XA patent/SG11201708303XA/en unknown
- 2016-05-18 NZ NZ737355A patent/NZ737355A/en unknown
- 2016-05-18 JP JP2017559671A patent/JP6629885B2/en active Active
- 2016-05-20 TW TW105115843A patent/TWI650320B/en active
-
2017
- 2017-11-01 US US15/801,124 patent/US10669260B2/en active Active
- 2017-11-12 IL IL255589A patent/IL255589B/en active IP Right Grant
- 2017-11-15 ZA ZA2017/07749A patent/ZA201707749B/en unknown
-
2018
- 2018-09-27 HK HK18112447.4A patent/HK1253065A1/en unknown
-
2019
- 2019-07-18 JP JP2019132614A patent/JP2019194253A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016266942A1 (en) | 2017-12-07 |
| JP2019194253A (en) | 2019-11-07 |
| KR102055491B1 (en) | 2019-12-12 |
| NZ737355A (en) | 2019-05-31 |
| RU2017139768A3 (en) | 2019-06-24 |
| MX2017014567A (en) | 2018-06-28 |
| EP3298004B1 (en) | 2021-01-06 |
| CA2986141A1 (en) | 2016-12-01 |
| JP6629885B2 (en) | 2020-01-15 |
| AU2016266942B2 (en) | 2018-10-18 |
| EP3298004A1 (en) | 2018-03-28 |
| CN107787320A (en) | 2018-03-09 |
| ZA201707749B (en) | 2020-05-27 |
| CN107787320B (en) | 2020-12-04 |
| US9822098B2 (en) | 2017-11-21 |
| TW201710252A (en) | 2017-03-16 |
| US20160362397A1 (en) | 2016-12-15 |
| WO2016191178A1 (en) | 2016-12-01 |
| IL255589A (en) | 2018-01-31 |
| RU2017139768A (en) | 2019-06-24 |
| US10669260B2 (en) | 2020-06-02 |
| IL255589B (en) | 2020-07-30 |
| US20180065952A1 (en) | 2018-03-08 |
| TWI650320B (en) | 2019-02-11 |
| RU2694895C2 (en) | 2019-07-18 |
| CA2986141C (en) | 2020-07-28 |
| HK1253065A1 (en) | 2019-06-06 |
| KR20180005174A (en) | 2018-01-15 |
| JP2018515545A (en) | 2018-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1253065A1 (en) | Compounds targeting proteins, compositions, methods, and uses thereof | |
| ZA201701168B (en) | Antibodies, compositions, and uses | |
| GB2561629B (en) | Methods, Compositions and uses relating thereto | |
| IL275435A (en) | Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof | |
| GB2560212B (en) | Methods, compositions and uses relating thereto | |
| GB2554485B (en) | Methods, compositions and uses relating thereto | |
| PT3552017T (en) | Compounds, compositions and methods | |
| IL258570A (en) | Stable protein compositions | |
| HK1247927A1 (en) | Novel compositions, uses and methods for making them | |
| IL237852A0 (en) | Anti amphiregulin antibodies, compositions comprising same and uses thereof | |
| GB201513614D0 (en) | Compositions, compounds and methods and uses relating thereto | |
| GB2560213B (en) | Methods, compositions and uses relating thereto | |
| GB2559644B (en) | Methods, compositions and uses relating thereto | |
| GB2559645B (en) | Methods, compositions and uses relating thereto | |
| GB201715799D0 (en) | Methods, compositions and uses relating thereto | |
| IL259900A (en) | Aminoazole derivatives, compositions containing same and uses thereof | |
| IL255042A0 (en) | Bolaamphiphilic compounds, compositions and uses thereof | |
| GB201616647D0 (en) | Methods, compositions and uses relating thereto | |
| GB201616676D0 (en) | Methods, compositions and uses relating thereto | |
| GB201616745D0 (en) | Methods, compositions and uses relating thereto | |
| GB201616746D0 (en) | Methods, compositions and uses relating thereto | |
| GB201616753D0 (en) | Methods, compositions and uses relating thereto | |
| GB201616678D0 (en) | Methods, compositions and uses relating thereto | |
| GB201616648D0 (en) | Methods, compositions and uses relating thereto | |
| GB201616645D0 (en) | Methods, compositions and uses relating thereto |